Genfit Ends Phase 3 Trial of NASH Drug Elanfibranor After Finding No Benefit

French drugmaker Genfit has ended a phase 3 trial of elafibranor for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis after the drug failed to show efficacy.

The company said the drug did not resolve the condition in 1,070 treated patients without worsening of their fibrosis.

Genfit said it will now focus on developing elanfibranor for primary biliary cholangitis, a chronic liver disease in which the bile ducts are slowly destroyed.